Phase 3 N=167 Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer
Breast Cancer · Sentinel Lymph Node · Breast Neoplasms
Primary: Median Post-Procedural Pain Score — 2; 2; 4; 4 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=194 Safety and Efficacy of Emixustat in Stargardt Disease
Stargardt Disease
Primary: Mean Rate of Change in Total Area of Macular Atrophy, as Measured by Fundus Autofluorescence (FAF) — 1.280; 1.309 Rate of change from BL (mm^2/yr)
Phase 3 N=544 Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
Hidradenitis Suppurativa
Primary: Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR50) — 42.3; 46.1; 31.2 Percentage of Participants — p=0.0149
Phase 3 N=23 Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Mydriasis · Dilation
Primary: Safety Measurements — 0.3; -0.2; 1.6; 0.0 score on a scale
Phase 3 N=78 Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
Fabry Disease
Primary: Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) — -2.514; -2.155 mL/min/1.73 m^2/year
Phase 3 N=134 Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
Acanthamoeba Keratitis
Primary: Clinical Resolution Rate — 84.8; 88.5 percentage of participants
Phase 3 N=1,331 ACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)
Covid19
Primary: Time to Sustained Recovery in Days — 12; 13 days
Phase 3 N=165 FACBC Outcomes for Post Prostatectomy
Prostate Cancer
Primary: Failure-free Survival — 75.5; 63.0 Percentage of participants
Phase 3 N=68 Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy
Pain, Postoperative
Primary: Total Opioid Pain Medications Required 0-3h Post op in Morphine Milligram Equivalents (MME) — 2.00; 5.32 morphine milligram equivalents (MME)
Phase 3 N=368 Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)
Mydriasis · Dilation
Primary: Percent of Subjects' Study Eyes With Pupil Diameter Returning to Baseline — 142; 7; 102; 117 Participants
Phase 3 N=308 Efficacy Study of Patient Preoperative Preps In-vivo
Surgical Skin Preparation
Primary: Log Change (Reduction) in Skin Flora on the Inguinal Region at 10 Minutes — 3.60; 3.61; 1.15 Log10 CFU/cm^2
Phase 3 N=172 A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
Cystic Fibrosis
Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 160; 26…
Phase 3 N=20 An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Primary: Parts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 3; 3 Participants
Phase 3 N=150 A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)
Coronavirus Disease (COVID-19)
Primary: Main Part: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers to the Ancestral Strain (Wild-type Virus) on Day 15 Compared With That Observed on Day 36 in…
Phase 3 N=1,923 A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
SARS-CoV-2 Infection
Primary: Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection — 12.2; 31.8; 89.6 events per 100 person years